Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial

European Journal of Cancer ◽

10.1016/j.ejca.2016.03.010 ◽

2016 ◽

Vol 60 ◽

pp. 117-124 ◽

Author(s):

Philippe Aftimos ◽

Laura Polastro ◽

Lieveke Ameye ◽

Christiane Jungels ◽

Jalal Vakili ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Pivotal Phase ◽

Phase Iii Trial ◽

Expanded Access ◽

Expanded Access Program ◽

Download Full-text

Lapatinib as salvage therapy in metastatic breast cancer: Preliminary results from an expanded access program

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.12006 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 12006-12006

Author(s):

F. Giotta ◽

A. Latorre ◽

G. Monticelli ◽

S. Oliva ◽

D. Albano ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Salvage Therapy ◽

Metastatic Breast ◽

Preliminary Results ◽

Expanded Access ◽

Expanded Access Program ◽

Download Full-text

Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer

Cancer Research and Treatment ◽

10.4143/crt.2017.446 ◽

2018 ◽

Vol 50 (4) ◽

pp. 1226-1237 ◽

Author(s):

Renaud Sabatier ◽

Véronique Diéras ◽

Xavier Pivot ◽

Etienne Brain ◽

Henri Roché ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Expanded Access ◽

Expanded Access Program ◽

Microtubules Inhibitors ◽

Download Full-text

A single-institution experience from the Lapatinib Expanded Access Program – effect of lapatinib and capecitabine combination therapy on CNS metastases in patients with ErbB2+ metastatic breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70735-3 ◽

2008 ◽

Vol 6 (7) ◽

pp. 175 ◽

Author(s):

B. Kaufman ◽

R. Weitzen ◽

A. Goldfarb ◽

N. Ephrat ◽

I. Kuchuk ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Combination Therapy ◽

Metastatic Breast ◽

Single Institution ◽

Cns Metastases ◽

Expanded Access ◽

Program Effect ◽

Expanded Access Program ◽

Download Full-text

Abstract P3-14-15: Lapatinib Plus Capecitabine in Trastuzumab Pre-Treated HER2- Positive Metastatic Breast Cancer: The Canadian Lapatinib Expanded Access Program Experience

10.1158/0008-5472.sabcs10-p3-14-15 ◽

2010 ◽

Author(s):

J Chang ◽

S Chia ◽

C Prady ◽

K Haider ◽

D Grenier ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Her2 Positive ◽

Expanded Access ◽

Expanded Access Program ◽

Download Full-text

Is epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trial

British Journal of Cancer ◽

10.1038/sj.bjc.6603096 ◽

2006 ◽

Vol 94 (9) ◽

pp. 1233-1236 ◽

Author(s):

C Pacilio ◽

◽

A Morabito ◽

F Nuzzo ◽

A Gravina ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Adjuvant Treatment ◽

Metastatic Breast ◽

Phase Iii ◽

Single Centre ◽

Phase Iii Trial ◽

Line Chemotherapy

Download Full-text

Phase III trial of chemotherapy ? HerceptinR in metastatic breast cancer

Breast Cancer Research ◽

10.1186/bcr-2001-68448 ◽

2001 ◽

Vol 3 (1) ◽

Author(s):

Fatima Cardoso

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trial

Download Full-text

A phase III trial of exemestane plus bevacizumab maintenance therapy in patients with metastatic breast cancer after first-line taxane and bevacizumab: a GINECO group study

Annals of Oncology ◽

10.1093/annonc/mdw077 ◽

2016 ◽

Vol 27 (6) ◽

pp. 1020-1029 ◽

Author(s):

O. Trédan ◽

P. Follana ◽

I. Moullet ◽

C. Cropet ◽

S. Trager-Maury ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Maintenance Therapy ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trial

Download Full-text

Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

Yearbook of Oncology ◽

10.1016/s1040-1741(10)79503-8 ◽

2010 ◽

Vol 2010 ◽

pp. 28-29

Author(s):

J.T. Thigpen

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Independent Review

Download Full-text

OT2-01-02: First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2−Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase III Trial.

10.1158/0008-5472.sabcs11-ot2-01-02 ◽

2011 ◽

Author(s):

S Beslija ◽

T Brodowicz ◽

R Greil ◽

MJ Inbar ◽

Z Kahán ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Locally Recurrent

Download Full-text

Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

10.1158/0008-5472.sabcs13-s5-07 ◽

2013 ◽

Author(s):

JB Smerage ◽

WE Barlow ◽

DF Hayes ◽

EP Winer ◽

B Leyland-Jones ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Cancer Patients ◽

Metastatic Breast ◽

Circulating Tumor Cell ◽

Phase Iii ◽

Breast Cancer Patients ◽

Phase Iii Trial

Download Full-text